MedTrace Logo

Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00758459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2011-08-19

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.

Conditions

Interventions

DRUG

AZD1236

oral tablet, 75 mg, twice daily during 6 weeks

DRUG

Placebo

Dosing to match AZD1236

Sponsors & Collaborators

Principal Investigators

  • Helgo Magnussen, MD, Professor · Pulmonary research institute at Hospital Grosshansdorf, Wöhrendamm, Grosshansdorf Germany

  • Andrew Lockton, MD · AstraZeneca R&D Charnwood

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Completion
2009-03-31

Countries

  • Bulgaria
  • Finland
  • Germany
  • Hungary
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00758459 on ClinicalTrials.gov